Sanofi Demonstrates Commitment to Innovative Diabetes Care at International Diabetes Technology Conference

Paris, France (ots) -

- Data presented at ATTD by Sanofi will focus on the company's
integrated portfolio of therapeutic solutions, blood glucose
monitoring, insulin delivery and contributions to advancing
diabetes research -

Sanofi (EURONEXT : SAN and NYSE : SNY) announced today that its
comprehensive portfolio of innovative diabetes solutions will be
presented at the International Conference on Advanced Technologies &
Treatments for Diabetes (ATTD) in Paris, France (February 27 - March
2). The annual ATTD conference is the leading diabetes technology
meeting in Europe, and Sanofi will showcase its commitment to
advancing therapeutic solutions and diabetes care technology aimed at
improving patient outcomes.

Abstracts include the latest clinical data on the early benefits
of Lantus® (insulin glargine), the accuracy, reliability and ease-of-
use of the BGStar® and iBGStar® blood glucose meters, and the
SoloSTAR® insulin delivery device. The study design of the biggest
multi-national register of diabetes research in the young, TEENS,
will also be featured.

In addition, Sanofi will sponsor a plenary satellite symposium at
ATTD titled "Technology: Contributing to Diabetes Management Today
and Tomorrow" which will provide an overview of current and future
treatments, tools and projects to facilitate clinical decision making
and empower patients to take control of their diabetes. The session
will conclude with a presentation on the artificial pancreas in
children.

"Today, effective diabetes management is increasingly a matter of
simplifying day-to-day routines for people living with the condition.
This means we need comprehensive approaches to diabetes care based on
technological advances," said Pierre Chancel, Senior Vice President,
Sanofi, Global Diabetes. "Sanofi's diabetes teams are dedicated to
providing innovative and integrated technological solutions combined
with patient support services that help people with diabetes
effectively manage their disease while living the lives they want to
live."

Highlights of the data being presented are as follows (abstracts
are available on the ATTD website www2.kenes.com/attd):

iNewTrend study: "Effect of Glucose Monitoring with Smartphone
Integration on Metabolic Control and Compliance in Type 1 Diabetes
(iNew Trend): Study Design"
When: Session 26: Oral Presentations, Saturday 2 March, 12:20
- 12:30pm CET
Presenter: V. Cherubini, Polytechnic University of Marche, Ancona,
Italy
Where: CNIT Paris La Defense Exhibition Hall, Hall III

EARLY LANTUS study: "Early Onset of Glycaemic Improvements after
Insulin Initiation with Insulin Glargine in Patients with Type 2
Diabetes Mellitus Uncontrolled with OADs: Pooled Analysis from
Clinical Trials"
When: Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET
Presenter: D.R. Owens, Institute of Molecular and Experimental
Medicine, Cardiff, UK
Where: CNIT Paris La Defense Exhibition Hall, Poster Area

LANTUS survey: "Survey on Physician Experiences in Initiation of
Insulin in Type 2 Diabetes Patients: Preliminary Results for Insulin
Glargine"
When: Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET
Presenter: R. Roussel, Diabetology, Endocrinology and Nutrition
Department, Paris, France
Where: CNIT Paris La Defense Exhibition Hall, Poster Area

TEENS study: "International Evaluation of Diabetes Management,
Glycaemic Control and Quality of Life in Youth with Type 1 Diabetes:
the TEENS Study"
When: E-Poster Session 4, Friday 1 March, 10:00am CET
Presenter: L. Laffel, Harvard Medical School, Boston, USA
Where: CNIT Paris La Defense Exhibition Hall, Exhibition Area,
Poster Station 2

BGStar® and iBGStar® abstracts include:

"Assessment of Ascorbic Acid and Acetaminophen Interference on the
Performance of Blood Glucose Meters for Patient Self-Testing"
When: Poster Session, Thursday 28 February, 8:00am - 17:00pm
CET
Presenter: A. Pfützner, IKFE - Institute for Clinical Research and
Development, Mainz, Germany
Where: CNIT Paris La Defense Exhibition Hall, Poster Area

"Laboratory Study for Evaluation of the Influence of Temperature and
Humidity on Blood Glucose Measurements with BGStar and iBGStar"
When: Poster Session, Thursday 28 February, 8:00am - 17:00pm
CET
Presenter: A. Pfützner, IKFE - Institute for Clinical Research and
Development, Mainz, Germany
Where: CNIT Paris La Defense Exhibition Hall, Poster Area

"Performance of Current Blood Glucose Meters in Compliance with the
New Draft Clinical ISO15197: 2010 Accuracy Criteria"
When: Poster Session, Thursday 28 February, 8:00am - 17:00pm
CET
Presenter: A. Pfützner, IKFE - Institute for Clinical Research and
Development, Mainz, Germany
Where: CNIT Paris La Defense Exhibition Hall, Poster Area

"Impact of Strip Filling on the Performance of Glucose Meters for
Patient Self-Testing"
When: Poster Session, Thursday 28 February, 8:00am - 17:00pm
CET
Presenter: A. Pfützner, IKFE - Institute for Clinical Research and
Development, Mainz, Germany
Where: CNIT Paris La Defense Exhibition Hall, Poster Area

SoloSTAR® abstracts include:

"Field Study on Rotational Speeds and Angles used by Patients Dialing
a Dose on Four Different Disposable Insulin Pens"
When: E-Poster Session 1, Thursday 28 February, 10:05am CET
Presenter: A. Friedrichs, LWS Risk Management Consult GmbH,
Brannenburg, Germany
Where: CNIT Paris La Defense Exhibition Hall, Exhibition Area,
Poster Station 1

"Torque for Dose Dialing of Four Disposable Insulin Pens SoloSTAR,
FlexTouch, FlexPen, and KwikPen: Results of a Laboratory Study"
When: Poster Session 2, Friday 1 March, 8:00am - 17:00pm CET
Presenter: A. Friedrichs, LWS Risk Management Consult GmbH,
Brannenburg, Germany
Where: CNIT Paris La Defense Exhibition Hall, Poster Area

Sanofi-Sponsored Plenary Satellite Symposium:

"Technology: Contributing to Diabetes Management Today and Tomorrow"
When: Session 8: Plenary Satellite Symposium, Thursday 28
February, 15:00 - 16:30pm CET
Chairman: L. Heinemann, Profil Institute for Metabolic Research,
Neuss, Germany
Where: CNIT Paris La Defense Exhibition Hall, Hall I

About Diabetes

Diabetes is a chronic disease that occurs as type 1 diabetes,
which is an autoimmune disease characterized by the lack of insulin
(the hormone that regulates blood glucose concentrations) production
by the pancreas, and type 2, a metabolic disorder in which there are
two main biological defects: a deficient production of insulin and
reduced ability of the body to respond to the insulin being produced.
Type 1 and type 2 diabetes are characterized by an increase in blood
glucose concentrations (hyperglycemia). Over time, uncontrolled
hyperglycemia leads to the macrovascular and microvascular
complications of diabetes. Macrovascular complications, which affect
the large blood vessels, include heart attack, stroke and peripheral
vascular disease. Microvascular complications affect the small blood
vessels of the eyes (retinopathy), kidney (nephropathy) and nerves
(neuropathy). The global incidence of diabetes is growing at an
alarming rate, with more than 371 million people worldwide living
with the condition today.[1]

About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of
diabetes by delivering innovative, integrated and personalized
solutions. Driven by valuable insights that come from listening to
and engaging with people living with diabetes, the Company is forming
partnerships to offer diagnostics, therapies, services and devices,
including intelligent blood glucose monitoring systems. Sanofi
markets both injectable and oral medications for people with type 1
or type 2 diabetes.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients'
needs. Sanofi has core strengths in the field of healthcare with
seven growth platforms: diabetes solutions, human vaccines,
innovative drugs, consumer healthcare, emerging markets, animal
health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN)
and in New York (NYSE: SNY).

Forward-Looking Statements

This press release contains forward-looking statements. Forward-
looking statements are statements that are not historical facts.
These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential, and
statements regarding future performance. Forward- looking statements
are generally identified by the words "expects", "anticipates",
"believes", "intends", "estimates", "plans" and similar expressions.
Although Sanofi's management believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject
to various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could cause
actual results and developments to differ materially from those
expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the
Group's ability to benefit from external growth opportunities, trends
in exchange rates and prevailing interest rates, the impact of cost
containment policies and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi,
including those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31, 2011. Other than as
required by applicable law, Sanofi does not undertake any obligation
to update or revise any forward-looking information or statements.

[1] International Diabetes Federation. IDF Diabetes Atlas, 5th
edn. Brussels, Belgium: International Diabetes Federation, 2011.
http://www.idf.org/diabetesatlas (Accessed: February 14, 2013 - 17:30
pm)

Contacts:
Global Diabetes Division
Diagnostics and Delivery Solutions
Milena Saleh
Mobile: +49 173 68 96 040
E-mail: Milena.Saleh@sanofi.com